Kojder Klaudyna, Jarosz Konrad, Bosiacki Mateusz, Andrzejewska Agata, Zacha Sławomir, Solek-Pastuszka Joanna, Jurczak Anna
Anesthesiology and Intensive Care Department, Pomeranian Medical University, 70-210 Szczecin, Poland.
Department of Specialist Nursing, Pomeranian Medical University, 70-210 Szczecin, Poland.
J Clin Med. 2023 Oct 20;12(20):6638. doi: 10.3390/jcm12206638.
Subarachnoid Hemorrhage (SAH) is one of the acute neurological conditions that is associated with high mortality and recovery failure rates. In recent years, due to the development of endovascular and classical techniques, the mortality rate after SAH has decreased. Currently, more research is focused on understanding the molecular mechanisms underlying SAH. Methods of treatment are investigated in order to obtain the best treatment result, not only survival. One of the drugs used in stroke, including SAH, is Cerebrolysin. It is a mixture of neuropeptides that has similar properties to neurotrophic factors. Its positive impact on strokes has been analyzed; however, there are no meta-analyses concerning only the subpopulation of patients diagnosed with SAH in the current literature. Therefore, we conducted a meta-analysis of available clinical trials to evaluate the effect of Cerebrolysin on the treatment outcome. The data suggest a positive effect of Cerebrolysin on the mortality of SAH patients. However, further randomized clinical trials with larger groups of patients are needed to draw final conclusions.
蛛网膜下腔出血（SAH）是一种急性神经系统疾病，与高死亡率和康复失败率相关。近年来，由于血管内和传统技术的发展，SAH后的死亡率有所下降。目前，更多的研究集中在了解SAH潜在的分子机制。为了获得最佳治疗效果，不仅是生存，还对治疗方法进行了研究。用于治疗中风（包括SAH）的药物之一是脑蛋白水解物。它是一种神经肽混合物，具有与神经营养因子相似的特性。已经分析了其对中风的积极影响；然而，目前文献中没有仅针对诊断为SAH的患者亚群的荟萃分析。因此，我们对现有临床试验进行了荟萃分析，以评估脑蛋白水解物对治疗结果的影响。数据表明脑蛋白水解物对SAH患者的死亡率有积极影响。然而，需要进一步进行更大患者群体的随机临床试验才能得出最终结论。
